It will be of great interest to determine whether targeting of AKT-mTOR-STAT3 axis-dependent CCR1 expression can be a potential therapeutic strategy for the management of triple-negative breast cancer. This evidence concerns the gene STAT3 and triple-negative breast carcinoma.